This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pagnoux, C Articles by Guillevin, L Search for Related Content PubMed PubMed Citation Articles by Pagnoux, C Articles by Guillevin, L Social Bookmarking                         What's this?

Indications for plasma exchange in systemic lupus erythematosus in 2005

Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris,Université René Descartes, Paris, France, christian.pagnoux{at}psl.aphp.fr

J-M Korach

Intensive Care Unit, General Hospital, Chalons-en-Champagne, France

L Guillevin

Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris,Université René Descartes, Paris, France

Plasma exchange can remove putative pathogenic autoantibodies and circulating immune complexes from the blood of patients with systemic lupus erythematosus (SLE). However, their efficacy has only been supported by noncontrolled and/or retrospective studies. Nonetheless, PE may still be of relevance in some selected SLE patients and as adjunctive therapy, in combination with corticosteroids (CS) and other immunosuppressant(s). We review herein the principal historical steps of the use of plasma exchange to treat SLE, based upon the main trials and case reports that have highlighted its most pertinent indications. Acute life-threatening manifestations and severe therapy-resistant manifestations, like refractory SLE renal disease, diffuse alveolar hemorrhage, neuropsychiatric SLE, thrombotic thrombocytopenic purpura, catastrophic antiphospholipid syndrome, hyperviscosity syndrome and cryoglobulinemia, are the indications for which plasma exchange might have a beneficial therapeutic role. Although few SLE patients undergo plasma exchange each year nowadays (10-20 per year in France), adverse events are very rare and recent advances in plasma exchange technologies, like immunoadsorption, might, in the future, counterbalance their cost and broaden their place in the therapeutic armamentarium for SLE.

Key Words: immunoadsorption • plasma exchange • plasmapheresis • systemic lupus erythematosus

Lupus, Vol. 14, No. 11, 871-877 (2005)
DOI: 10.1191/0961203305lu2174rr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Todd and K. Costenbader Dyspnoea in a young woman with active systemic lupus erythematosus Lupus, August 1, 2009; 18(9): 777 - 784. [Abstract] [PDF]